Smith Group Asset Management’s Standard BioTools LAB Stock Holding History

Smith Group Asset Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-24,960	Closed	-$116K	–	390
2019 Q3	$116K	Hold	24,960	–	–	﹤0.01%	228
2019 Q2	$308K	Buy	+24,960	New	+$318K	0.01%	174

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Smith Group Asset Management's LAB Position: Q4 2019 in Review

Smith Group Asset Management sold out of Standard BioTools (LAB) in Q4 2019, closing a stake of 24,960 shares — an estimated $116K sold.

Smith Group Asset Management first reported a position in LAB in Q2 2019 and held it in 2 quarters. The position peaked at $308K in Q2 2019. 99 funds tracked by Wall St. Rank hold LAB as of Q4 2019.

Smith Group Asset Management reported no remaining Standard BioTools position as of Q4 2019 after selling out during the quarter.
Smith Group Asset Management sold 24,960 Standard BioTools shares in Q4 2019, an estimated $116K.
Smith Group Asset Management first reported a position in Standard BioTools in Q2 2019 and held it in 2 quarters.
Smith Group Asset Management's Standard BioTools position peaked at $308K in Q2 2019.
99 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2019.

Based on Smith Group Asset Management's 13F filing for Q4 2019, filed 4 Feb 2020.